This stock will need some sort of catalyst for a re-rate....

This stock will need some sort of catalyst for a re-rate.
Increased divs, progress on the pharma, pricing for the big harvests or even a substantial holder notice (that isn't UBS).
Failing that I think it will trade strongly leading up to the yearly results but until then who knows.

Interestingly there is big volumes on the buy side, and like yesterday I think this will close strongly.